Evidence is emerging that antibody concentrations decrease more rapidly in patients with IBD treated with anti-TNF drugs and that these patients are at greater risk of breakthrough infection following two doses of vaccine than patients with IBD treated with vedolizumab.6, 7, 8. Here, TNF is linked to inflammatory bowel disease.